Completed × NIH × Congenital Abnormalities × Clear all
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT00462605 2017-07-18

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 5 charts
NCT00275080 2014-08-27

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00096122 2014-05-26

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 5 charts
NCT00890747 2014-03-17

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00438958 2014-03-05

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 3 Completed
230 enrolled
NCT00005863 2013-12-19

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
NCT00005823 2013-12-18

Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Completed
2,000 enrolled
NCT00098423 2013-09-30

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00301938 2013-09-30

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
NCT00064090 2013-07-18

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00006363 2013-06-04

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
720 enrolled
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
NCT00521430 2013-03-26

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

National Cancer Institute (NCI)

Phase NA Completed
30 enrolled
NCT00569283 2013-03-26

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
NCT00627666 2013-03-26

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00095797 2013-02-08

XK469R in Treating Patients With Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00084916 2013-01-23

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

National Cancer Institute (NCI)

Phase 2 Completed
74 enrolled